Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and autoimmune diseases. Estrella has no approved products and no revenue. Its lead program, EB103, is a CD19-targeting T-cell therapy built on its proprietary ARTEMIS platform, currently in Phase II clinical trials (STARLIGHT-1) targeting patients with relapsed or refractory B-cell cancers. Phase II is expected to complete in early 2027. The pipeline also includes EB104, a dual CD19/CD22-targeting therapy in pre-IND preparation designed to prevent tumor escape, and EB201, a preclinical ARTEMIS-based therapy targeting Systemic Lupus Erythematosus. Estrella's central differentiating claim is that ARTEMIS uses an Antibody-T Cell Receptor architecture that more closely mimics natural T-cell activation than conventional CAR-T therapies, potentially reducing severe side effects like Cytokine Release Syndrome and neurotoxicity. If this safety profile holds, Estrella argues EB103 could be administered in community outpatient settings rather than specialized cancer centers, expanding the addressable patient population. Estrella does not manufacture EB103 itself — it relies on Eureka Therapeutics, its parent technology licensor, for manufacturing and clinical services under a $33M services agreement, and holds an exclusive license from Eureka to commercialize ARTEMIS-based products targeting CD19 and CD22 worldwide, excluding Greater China and ASEAN. If approved, Estrella would sell EB103 to hospitals and cancer centers and pay Eureka royalties and milestone payments.